• Publications
  • Influence
Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies.
TLDR
Two neutralizing epitopes on SIV are analogous to similar epitopes recently described in HIV-1, and three MAbs binding to the V3 region of SIV failed to neutralize infectivity, suggesting that this region in SIV may by functionally different from the V 3 loop in HIV -1. Expand
Production and of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins.
TLDR
Although similar titres were obtained with some MAb against other SIV and HIV antigens, the presence of isolate specific and shared group epitopes was demonstrated and the neutralizing MAb did not react with denatured antigen in Western blot suggesting that they may recognize conformational epitopes. Expand
Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells
TLDR
Findings show that live-attenuated vaccine can confer protection against SIV in macaques, and the mechanism of this potent protection must be understood and reproduced by less hazardous means. Expand
Effects of natural sequence variation on recognition by monoclonal antibodies neutralize simian immunodeficiency virus infectivity
TLDR
Radioimmunoprecipitation analysis demonstrated that sequence changes in variable regions 4 and 5 (V4/V5) were primarily responsible for the loss of recognition of the 1-12 variant of SIVmac. Expand
Histopathological changes in simian immunodeficiency virus infection
TLDR
The histological lesions were studied in monkeys infected with simian immunodeficiency virus for periods ranging from nine weeks to 18 months and found that the range of opportunistic infections was small compared with that in human AIDS patients, although two monkeys had Pneumocystis carinii pneumonia. Expand
Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency
TLDR
Despite strong immune responses to the vaccine there was no evidence that it protected against challenge with this chimeric virus, and the antigenic divergence between vaccine and challenge virus or the increased virulence of the challenge virus may be responsible for the inability of this vaccine to protect against infection by SHIV(SF33). Expand
Strategies for AIDS vaccines.
TLDR
There are now three possible approaches to an AIDS vaccine which are being actively pursued and the immune responses appear to be transient and the antibodies induced do not neutralize the primary isolates of HIV which are circulating in the population. Expand
In situ hybridization and immunolabelling study of the early replication of simian immunodeficiency virus (SIVmacJ5) in vivo.
TLDR
Results indicate that, even following intravenous challenge, a major site of the initial replication of SIV is gut-associated lymphoid tissue, and vaccines that induce protection at this site may be superior, even against parenteral challenge. Expand
Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum.
TLDR
The failure of passive immunization to transfer protection indicates that serum components alone are not sufficient to mediate the potent protection obtained using live attenuated vaccines. Expand
The use of the polymerase chain reaction for the detection of Simian immunodeficiency virus in experimentally infected macaques.
A rapid, non-radioactive assay for the detection of proviral Simian immunodeficiency virus (SIV) in tissue-culture cells is described. The assay is based on the co-amplification of the SIV env andExpand
...
1
2
3
...